Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aspen Aerogels (ASPN) Operating Leases (2019 - 2025)

Aspen Aerogels' Operating Leases history spans 7 years, with the latest figure at $21.1 million for Q4 2025.

  • For the quarter ending Q4 2025, Operating Leases fell 8.68% year-over-year to $21.1 million, compared with a TTM value of $21.1 million through Dec 2025, down 8.68%, and an annual FY2025 reading of $21.1 million, down 8.68% over the prior year.
  • Operating Leases for Q4 2025 was $21.1 million at Aspen Aerogels, up from $20.7 million in the prior quarter.
  • The five-year high for Operating Leases was $23.7 million in Q3 2024, with the low at $4.1 million in Q1 2021.
  • Average Operating Leases over 5 years is $17.8 million, with a median of $20.9 million recorded in 2025.
  • Year-over-year, Operating Leases soared 261.16% in 2021 and then dropped 12.62% in 2025.
  • Tracing ASPN's Operating Leases over 5 years: stood at $13.0 million in 2021, then grew by 3.58% to $13.5 million in 2022, then skyrocketed by 62.8% to $21.9 million in 2023, then grew by 5.67% to $23.1 million in 2024, then decreased by 8.68% to $21.1 million in 2025.
  • Per Business Quant, the three most recent readings for ASPN's Operating Leases are $21.1 million (Q4 2025), $20.7 million (Q3 2025), and $21.5 million (Q2 2025).